|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|
Sep 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
|
Jan 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
How we treat higher-risk myelodysplastic syndromes
|
Dec 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
|
Jul 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution
|
Sep 2014
|
Blood
|
aplastic anemia
|
|
PNH and complement gene variants
|
Apr 2023
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Genetics of Progression From MDS to Secondary Leukemia
|
May 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Apr 2023
|
Blood
|
aplastic anemia
|
|
Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes
|
Jun 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria
|
Jun 2023
|
Blood
|
aplastic anemia
|
